NICE needs more rimonabant data

Rimonabant should not be used for the treatment of obese and overweight adults, says NICE.

More information on how the drug compares to diet and exercise, orlistat and sibutramine with regards to cost effectiveness is needed from manufacturers Sanofi Aventis, claimed NICE in a draft technology appraisal issued last week.

NICE also wants an assessment of the drug using the 5 per cent weight loss continuation rule to treatment with rimonabant at three, six, nine and 12 months.

Jeni Wilson, head of communications at Sanofi Aventis said: 'The consultation document represents the preliminary feedback of the appraisal committee and is not formal guidance on this technology.

'The preliminary thoughts of the committee may change after consultation.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus